Razolam

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Razolam

This overview provides a concise summary of Razolam's identity and general therapeutic purpose, adhering to safety and content restrictions.

Property Description
Active Ingredient Razola-1-one
Form Film-coated tablet (Oral)
Pharmacological Class Benzodiazepine
General Purpose Symptomatic management of acute anxiety and nervousness
Origin Synthetic compound

What Type of Drug is Razolam?

Razolam is the common designation for a medication containing the active ingredient Razola-1-one, a substance classified within the benzodiazepine pharmacological group. This class of agents is clinically recognized for producing depressant effects on the central nervous system. Razola-1-one is a purely synthetic compound, manufactured through chemical synthesis to ensure consistent purity and standardized potency in every dose.

As an orally administered drug, Razolam is typically formulated as a rapid-acting, film-coated tablet. This specific formulation is often utilized to facilitate a quick onset of action, which is a key consideration when managing sudden or acute anxiety attacks. Its form and chemical nature confirm its role as a psychoactive pharmaceutical.


What is the General Purpose of Razolam?

The primary therapeutic purpose of Razolam is the symptomatic relief of severe, disabling anxiety and heightened psychological tension. It is formally classified as an anxiolytic (anxiety-reducing) agent due to its established effect on nervous activity.

Its general application is primarily in managing acute episodes of severe distress or psychological crisis where a prompt calming effect is medically necessary. By producing a pronounced sedative action, Razolam helps patients achieve temporary stabilization. Its function is to provide symptomatic control, aiding in overall management during periods of high emotional tension without detailing the underlying physiological mechanism.

Regulatory References

  1. Browse Drug Classes

What side effects are possible with Razolam?

Possible side effects and safety information

The official safety profile for Razolam (Razola-1-one) is structured by government regulatory agencies based on frequency and body system involvement. As a central nervous system (CNS) depressant, the most frequently documented adverse reactions relate to its sedative properties.


Frequency-Classified Adverse Reactions

Adverse reactions are formally categorized based on regulatory standards for reporting frequency:

  • Very Common: Drowsiness and Sedation.
  • Common: Dizziness, Ataxia (impaired coordination), Reduced alertness, Fatigue, Muscle weakness, and Anterograde amnesia (memory impairment).
  • Uncommon / Rare: Includes paradoxical reactions (e.g., aggression, agitation), Jaundice, Blood dyscrasias, and Visual disturbances.

Serious Adverse Reactions and Safety Patterns

The regulatory documentation highlights specific, clinically significant risks. The use of Razolam is associated with the potential for physical dependence and addiction, and the abrupt cessation after prolonged use may lead to a severe Withdrawal Syndrome. Regulators also classify Respiratory Depression as a serious risk, especially when the medicine is used concurrently with other CNS depressants, such as opioids.

Safety notes specify that effects like drowsiness are generally more pronounced at the start of therapy. The risk of dependence is documented to increase with both the dose and the duration of treatment.


Population-Specific Safety Notes

The official label includes specific safety considerations for vulnerable populations. Older adults face an increased risk of CNS depression and associated ataxia, which contributes to the risk of falls. Razolam is contraindicated in patients with conditions such as Myasthenia Gravis and Severe Hepatic Insufficiency, as documented by health authorities.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents state that Razolam (Razola-1-one) overdose is typically characterized by a graded spectrum of Central Nervous System (CNS) depression. Documented clinical manifestations include somnolence, confusion, ataxia (impaired coordination), and lethargy. As toxicity increases, patients may exhibit more severe signs such as slurred speech (dysarthria) and reduced muscle tone (hypotonia).


Severe overdose scenarios, often involving exceptionally high doses or the co-ingestion of other CNS depressants like alcohol or opioids, carry a significantly elevated risk of life-threatening outcomes. The most serious officially documented manifestations are profound respiratory depression, significant hypotension, and coma. Due to this compounded risk, regulatory labeling provides specific warnings about combined use.


For any suspected overdose, the mandate is to seek immediate medical attention. Emergency services must be contacted immediately if the patient displays signs of severe CNS impairment, specifically including slowed or difficult breathing and loss of consciousness. Management, as described in official labeling, involves symptomatic and supportive treatment, including the maintenance of a patent airway and continuous cardiorespiratory monitoring by healthcare professionals. A specific benzodiazepine receptor antagonist, Flumazenil, is an officially recognized intervention for use in a controlled clinical environment.

Therapeutic Uses of Razolam

Razolam is a treatment option primarily utilized for the short-term management of specific mental health conditions. Its approved clinical domains center on helping to reduce the intensity of symptoms linked to anxiety disorders. Physicians may utilize this medication to help address Generalized Anxiety Disorder (GAD) or to assist in managing acute symptoms associated with Panic Disorder, which may include agoraphobia.

The benefit of Razolam is focused on providing relief from disruptive psychological and physical manifestations of acute distress, which can include overwhelming worry, tension, and functional impairment. The medication may be considered for the temporary management of difficulties with sleep or agitation when these symptoms are related to the core anxiety condition.


Quick Fact: Relief for Acute Distress

Regulatory References

  1. NIH MedlinePlus guidance on therapeutic classes

Eligibility and Restrictions for Use

Razolam use is strictly defined by regulatory guidelines to ensure appropriate population eligibility. The medication is absolutely contraindicated in several groups, including patients with a known hypersensitivity to Razola-1-one or any other benzodiazepine, those with acute narrow-angle glaucoma, and individuals diagnosed with severe respiratory insufficiency or severe hepatic impairment. Use is also prohibited when taking certain strong CYP3A inhibitors.

The drug is generally permitted for use in the adult population (18 to 65 years) under standard conditions. However, eligibility is constrained in specific populations. Pediatric use (under 18) is not established due to insufficient safety and efficacy data. For older adults, a lower starting dose is required due to increased sensitivity and risk.

Furthermore, use is not recommended during both pregnancy and lactation due to documented potential effects on the fetus or infant. Restricted use applies to patients with mild to moderate renal or hepatic impairment, and individuals with a history of drug or alcohol abuse require extreme caution due to addiction risk. Regulatory labeling classifies Razolam as not recommended for use as a single agent in treating depressive illnesses.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Razola-1-one (Razolam) based on its primary metabolic pathway and pharmacological properties.


Pharmacokinetic Interactions (Metabolic)

Razola-1-one is primarily cleared via the Cytochrome P450 3A (CYP3A4) enzyme system. Co-administration with strong CYP3A inhibitors significantly slows this clearance, resulting in a clinically relevant increase in Razolam’s plasma concentration (AUC).

The most significant restriction is the contraindication with potent inhibitors, including Ketoconazole and Itraconazole, as this combination is explicitly prohibited due to the risk of excessive exposure. Conversely, CYP3A inducers like Carbamazepine are documented to increase metabolic clearance, potentially leading to reduced systemic concentrations.


Pharmacodynamic Interactions

Interactions not based on metabolism, but on additive effects, are a major regulatory focus. Co-administration with other Central Nervous System (CNS) Depressants, such as Opioids and Barbiturates, results in an additive depressant effect on the CNS. This additive effect is associated with a formal regulatory warning due to the risk of profound sedation and respiratory depression.

Other Documented Substance Interactions

Official labeling requires restrictions on non-medicinal substances. Alcohol (Ethanol) is formally restricted due to the pronounced additive CNS depression. Furthermore, certain supplements and foods, such as Grapefruit Juice (a CYP3A inhibitor) and St. John's Wort (a CYP3A inducer), are documented to alter Razola-1-one's systemic exposure.

Mechanism of Action

Razolam, a triazolobenzodiazepine, exerts its primary action within the central nervous system (CNS). Its molecular target is the gamma-aminobutyric acid type A (GABAA) receptor, which is a pentameric ligand-gated chloride ion channel.

Razolam functions as a positive allosteric modulator of this receptor. It binds to a specific allosteric site located at the interface of the alpha and gamma subunits of the GABAA receptor complex . The binding does not activate the receptor directly but induces a conformational change that increases the affinity of the receptor for its endogenous agonist, gamma-aminobutyric acid (GABA).

This enhanced GABAergic signaling results in an increased frequency of chloride ion channel opening. The subsequent influx of negative chloride ions (Cl^-) into the postsynaptic neuron leads to hyperpolarization of the neuronal membrane, thereby decreasing neuronal excitability and making the cell less likely to fire an action potential. This downstream cascade results in a system-level depression of central nervous system activity, modulating various physiological functions controlled by inhibitory neural pathways.

Dosage and Administration Information

Razolam is administered exclusively via the oral route as a film-coated tablet. The medication should be swallowed whole using water and must not be crushed, chewed, or divided to maintain its intended delivery characteristics. Administration is permitted with or without food.

The established adult dosing schedule is structured to manage acute symptoms using divided daily doses, typically two to four times per day, ensuring a minimum interval of six hours between administrations. Initial dosing for symptomatic relief generally begins at 1 mg, split into divided portions throughout the day. The maintenance range is officially recognized between 0.5 mg and 4 mg daily, with a maximum recommended daily limit of 6 mg.

Official instructions mandate specific adjustments for vulnerable populations. For older adults or patients presenting with hepatic impairment, the starting dose must be significantly reduced, often by half, due to altered metabolism and potential sensitivity.

Razolam is designated for short-term use only, with treatment duration typically not exceeding two to four weeks. Consistent with this time-bound application, discontinuation of Razolam requires a gradual, medically guided tapering process to mitigate systemic changes.

Recent Clinical Evidence

Research evidence / Overview of Studies for Razolam


Evidence from Clinical Trials for Acute Anxiety and Nervousness

Research for Razolam (Razola-1-one) in the context of acute anxiety primarily involves short-term Randomized Controlled Trials (RCTs). These studies were used in research exploring how symptoms change over time, often comparing the drug against a placebo. Researchers focused on adults experiencing episodic or acute changes and heightened symptom activity. Studies reported measurements of changes observed in the intensity of anxiety symptoms during the study period. Data described patterns related to the measured onset of effect in the psychological and physical manifestations of acute distress. However, follow-up durations were limited in these studies, meaning there is limited information for long-term outcomes related to sustained control.


Evidence from Clinical Trials for Generalized Anxiety Disorder (GAD)

Research exploring GAD, a condition characterized by fluctuating manifestations, involves RCTs extending for several weeks (typically 6 to 12 weeks). Studies explored outcomes reflecting daily functioning or activity level, such as changes in persistent worry, psychological tension, and sleep disturbance. Findings describe patterns observed in the studies related to the measured change in symptom intensity during the defined treatment interval. Research also examined measurements related to the recurrence or persistence of symptoms. The results apply only to the populations studied and within the scope of the study duration. Evidence quality varies across studies, and long-term effects are not fully established.


What is Still Uncertain About Razolam

A primary research limitation is the lack of robust, controlled evidence for long-term outcomes that fully characterizes the use of Razolam over many months or years. Follow-up durations were limited in the key efficacy trials. Data for special populations, such as children or older adults with co-occurring conditions, remain insufficient, and findings were mixed for certain complex cases. Certainty remains low regarding the management of chronic GAD or Panic Disorder beyond the acute and intermediate treatment phases.

Key Studies & References Generalised anxiety disorder and panic disorder in adults: management (NICE Clinical Guideline CG113)

Frequently Asked Questions (FAQ)

Common questions about Razolam (FAQ)

Q: Does Razolam cause weight gain or weight loss?

A: According to the official product information and data from clinical studies, both weight increased (weight gain) and weight decreased (weight loss) have been reported as adverse reactions. These are described as effects observed during the research period for the medication.

Q: Is Razolam a narcotic or addictive substance?

A: Regulatory authorities classify Razolam as a Schedule IV controlled substance, which means it has approved medical uses but carries a potential for abuse. The official label notes that there are risks of abuse, misuse, and addiction associated with the use of this medication.

Q: How long does it usually take for Razolam to start working?

A: Studies and official information indicate that after a dose is swallowed, the medication is readily absorbed. Peak concentrations in the body have been measured to occur within approximately one to two hours after administration.

Q: Is it possible to take Razolam with common pain relievers like ibuprofen?

A: Regulatory documents do not list a specific pharmacokinetic or pharmacodynamic interaction with ibuprofen or other Nonsteroidal Anti-inflammatory Drugs (NSAIDs). However, it's generally advised to discuss all medications, including over-the-counter products, with a health professional.

Q: Can Razolam affect my sleep patterns?

A: Official safety data lists Drowsiness and Sedation as very common effects because Razolam is a central nervous system depressant. It is also noted that some patients have reported experiencing insomnia during the course of their treatment.

Q: Is Razolam safe for people who have kidney issues?

A: Dosing adjustment recommendations are provided in the regulatory information for patients with liver (hepatic) problems. However, specific dosing recommendations for people with severe kidney (renal) impairment are generally not established in the primary regulatory label information.

Q: Are there different versions or strengths of Razolam available?

A: According to the official Dosage Forms and Strengths section, the immediate-release tablets are available in multiple strengths. These commonly include 0.25 mg, 0.5 mg, 1 mg, and 2 mg.

Q: Is Razolam available over the counter, or is it prescription only?

A: Razolam is a prescription drug that requires authorization from a healthcare professional. It is also classified as a DEA Schedule IV controlled substance by regulatory agencies.

Q: Is Razolam generally taken in the morning or at night?

A: The official documentation states that the immediate-release formulation is typically given in divided doses throughout the day, often two to four times daily. Dosing is typically structured to be distributed as evenly as possible throughout waking hours.

Q: Does taking Razolam affect my ability to become pregnant?

A: Animal studies examining fertility did not indicate an effect on the ability to conceive. However, the use of Razolam is not recommended during pregnancy due to documented potential risks to the fetus.

Q: Do other conditions, like heart problems, prevent someone from using Razolam?

A: The official contraindications section lists conditions such as severe respiratory or liver problems, but it does not list specific heart problems or high blood pressure as formal contraindications to the medication’s use.

Q: How quickly does the effect of Razolam wear off?

A: The duration of the medication's presence in the body is characterized by its half-life, which describes the time it takes for half the dose to be cleared. In healthy adults, the average half-life has been measured at approximately 11.2 hours, although this can vary widely among individuals.

Q: Is there a generic version of Razolam?

A: Yes, regulatory documents and authorized generic listings confirm that generic versions of the active ingredient (Razola-1-one) are available.

Q: Does Razolam interact with birth control pills?

A: Razolam is processed by the CYP3A4 enzyme. While Razolam is not documented to directly affect contraceptives, the co-administration of certain substances that affect this enzyme (CYP3A4 inducers) could potentially reduce the concentration of Razolam in the body.

Q: Can Razolam be taken if I have high blood pressure?

A: High blood pressure (hypertension) is not listed as a formal condition that prevents someone from using Razolam in the official regulatory contraindications section. Caution is primarily focused on respiratory and liver conditions.

Q: Can I develop tolerance to Razolam over a long period?

A: The official product information notes that the emergence of anxiety symptoms between scheduled doses may reflect the development of tolerance to the medication. Tolerance is generally understood as a state where the body requires increased doses to achieve previous effects.

Q: Can I still take Razolam if I am taking over-the-counter cold medicine?

A: Many over-the-counter cold medicines contain other ingredients that are classified as CNS depressants (such as certain antihistamines). Official regulatory information documents that caution is needed because combining Razolam with other CNS depressants is documented to create an additive depressant effect.

Q: How long does Razolam stay in my system after the last dose?

A: The duration Razolam stays in the body is generally defined by its half-life, which describes the time it takes for half the dose to be cleared. For healthy adults, the mean elimination half-life is approximately 11.2 hours, but the actual time required for full clearance from the system may vary among individuals.

Q: What should I know about Razolam and driving or operating machinery?

A: As a central nervous system depressant, Razolam may cause drowsiness and reduced alertness (ataxia). The regulatory documentation notes that caution is necessary, particularly at the start of therapy, due to the potential for these effects to impair the safe operation of vehicles or complex machinery.

How should Razolam be stored and disposed of?

Storage and Disposal Requirements for Razolam

The storage and handling of Razolam (Razola-1-one oral tablets) must strictly follow official governmental regulatory mandates to ensure stability and public safety.


Storage Conditions

Razolam must be stored at controlled room temperature, typically 20 C to 25 C (68F to 77F), and should be protected from excessive heat and moisture. It is forbidden to refrigerate or freeze the tablets. The medication must be kept in its original container with the lid tightly closed to maintain product integrity. All Razolam should be stored out of the sight and reach of children due to safety requirements for all medicines.


️ Disposal Instructions

As Razolam is a controlled substance, disposal of unused or expired tablets must adhere to specific regulatory protocols. Patients are required to dispose of the product according to local regulations. The preferred method is returning the medication to an authorized drug take-back program. Disposal through household trash or flushing down the toilet is generally prohibited.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Razolam found in:

A-Z Index: